Curated News
By: NewsRamp Editorial Staff
April 22, 2024

Investors Eyeing Lucrative Opportunities in MASH Drug Market

TLDR

Investors are making a lot of money on obesity plays with a projected $71 billion market by 2032.
Obesity drugs, originally designed for managing blood sugar levels, have been repurposed to treat obesity, creating a crowded trade.
Drug makers are repurposing drugs to target metabolic dysfunction-associated steatohepatitis (MASH), offering hope for treating a serious liver condition.
Metabolic dysfunction-associated steatohepatitis (MASH) is a complicated disease on the regulatory front, with multiple druggable targets and innovative drug approaches.

Impact - Why it Matters

This news is important for investors looking to capitalize on the growing market for obesity drugs and the emerging focus on MASH drug development. It also sheds light on the potential impact of innovative drug targets in addressing metabolic dysfunction-associated steatohepatitis (MASH), a complex and severe liver disease. By understanding the latest trends in biotech and pharmaceuticals, readers can gain insights into potential investment opportunities and the future of drug development for metabolic disorders.

Summary

Investors are making a lot of money on obesity plays, with the global obesity drug market estimated to reach $71 billion by 2032. Drug makers like Eli Lilly and Viking Therapeutics are looking beyond GLP-1 inhibitors toward the MASH epidemic, targeting metabolic dysfunction-associated steatohepatitis (MASH) with promising clinical data. Multiple MASH drug targets including FGF21 agonists, galectin-3 antagonists, and thyroid hormone agonists are being pursued by companies like 89Bio Inc., Galectin Therapeutics, and CanFite Biopharma.

Source Statement

This curated news summary relied on this press release disributed by News Direct. Read the source press release here, Investors Eyeing Lucrative Opportunities in MASH Drug Market

blockchain registration record for the source press release.